Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Homocysteine in uremia.

Alessandra F Perna1, Diego Ingrosso, Cinzia Lombardi

  • 1First Division of Nephrology/Department of Pediatrics, School of Medicine, Second University of Naples (SUN), Naples, Italy. alessandra.perna@unina2.it

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|March 4, 2003
PubMed
Summary

High homocysteine (HHcy) is a cardiovascular risk factor, especially in chronic renal failure (CRF). Its mechanisms and the impact of lowering HHcy on cardiovascular risk are under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory biomarkers in the assessment of kidney function decline in Long Covid syndrome.

Kidney & blood pressure research·2026
Same author

Toward multimodal integration of colorectal cancer and chronic kidney disease: transcriptomic modeling as a framework for the SIRIO study "Spatial radiomics and transcriptomics to the discovery of the cross-link between colon cancer and chronic kidney disease".

Radiology and oncology·2026
Same author

Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use.

European heart journal. Imaging methods and practice·2025
Same author

GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.

International journal of molecular sciences·2025
Same author

Obstructive Sleep Apnea and Type 2 Diabetes: An Update.

Journal of clinical medicine·2025
Same author

Genome-Based Advances in Modeling Renal Ciliopathies and Enhancing Patient Care.

Kidney & blood pressure research·2025

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Biochemistry

Background:

  • Hyperhomocysteinemia (HHcy) is an independent cardiovascular risk factor, potentially contributing to 20% of cardiovascular deaths.
  • HHcy prevalence is high in chronic renal failure (CRF) and uremia, though some patients remain normohomocysteinemic.

Purpose of the Study:

  • To investigate the causes and consequences of hyperhomocysteinemia in chronic renal failure.
  • To explore the mechanisms of homocysteine toxicity and potential interventions.

Main Methods:

  • Review of existing literature on hyperhomocysteinemia in CRF.
  • Analysis of homocysteine's toxic mechanisms, including oxidative stress and hypomethylation.
  • Discussion of proposed nutritional and pharmacological interventions.

Related Experiment Videos

Main Results:

  • Hyperhomocysteinemia is common in CRF, with its exact cause (renal vs. extrarenal metabolism, uremic toxins) under scrutiny.
  • Homocysteine exerts toxicity through oxidative stress, nitric oxide binding, protein homocysteinylation, and hypomethylation.
  • Macromolecule hypomethylation is a common feature in CRF, potentially leading to functional consequences.

Conclusions:

  • Hyperhomocysteinemia is a significant cardiovascular risk factor, particularly in CRF.
  • Understanding homocysteine's toxic pathways is crucial for managing cardiovascular risk in CRF patients.
  • Clinical trials are pending to determine the efficacy of homocysteine-lowering therapies in reducing cardiovascular events.